MyeloXen: Phase I/IIa started

Xenetic said Pharmsynthez began a 3-part, open-label, Russian Phase I/IIa trial of MyeloXen in 26 subjects. The first part will enroll 6 healthy volunteers, while the second and third parts will each ...